ImmuPharma plc (LON:IMM – Get Free Report) rose 12.6% on Monday . The stock traded as high as GBX 6.98 and last traded at GBX 6.98. Approximately 2,726,278 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 2,871,186 shares. The stock had previously closed at GBX 6.20.
ImmuPharma Price Performance
The firm’s fifty day moving average price is GBX 7.91 and its 200-day moving average price is GBX 6.55. The company has a market cap of £36.20 million, a price-to-earnings ratio of -8.09 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- The $100 Trillion AI Story No One Is Telling You
- This stock gets a 94 out of 100
- 3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
